BG108315A - Състав и метод за повишаване на клетъчната гъстота в клетъчни култури, инфектирани с lentivirus - Google Patents

Състав и метод за повишаване на клетъчната гъстота в клетъчни култури, инфектирани с lentivirus Download PDF

Info

Publication number: BG108315A
Authority: BG; Bulgaria
Prior art keywords: cell culture; neomycin; virus; cell; amount
Prior art date: 2001-05-10

Application number

BG108315A

Other languages

Bulgarian (bg)

English (en)

Inventor

Anne Thomas

Terry Ng

Original Assignee

Wyeth

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-10

Filing date

2003-11-05

Publication date

2005-03-31

2003-11-05 Application filed by Wyeth filed Critical Wyeth

2005-03-31 Publication of BG108315A publication Critical patent/BG108315A/bg

Links

238000004113 cell culture Methods 0.000 title claims abstract description 96
238000000034 method Methods 0.000 title claims abstract description 30
230000001965 increasing effect Effects 0.000 title claims abstract description 13
239000000203 mixture Substances 0.000 title claims abstract description 9
241000713666 Lentivirus Species 0.000 title claims description 20
230000003115 biocidal effect Effects 0.000 claims abstract description 16
239000003242 anti bacterial agent Substances 0.000 claims abstract description 13
210000004027 cell Anatomy 0.000 claims description 58
229930193140 Neomycin Natural products 0.000 claims description 48
229960004927 neomycin Drugs 0.000 claims description 48
241000700605 Viruses Species 0.000 claims description 28
241000713800 Feline immunodeficiency virus Species 0.000 claims description 26
241000725303 Human immunodeficiency virus Species 0.000 claims description 17
230000012010 growth Effects 0.000 claims description 15
210000004698 lymphocyte Anatomy 0.000 claims description 13
108091003079 Bovine Serum Albumin Proteins 0.000 claims description 10
108010093965 Polymyxin B Proteins 0.000 claims description 10
229940098773 bovine serum albumin Drugs 0.000 claims description 10
229920000024 polymyxin B Polymers 0.000 claims description 10
229960005266 polymyxin b Drugs 0.000 claims description 10
241000282693 Cercopithecidae Species 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
206010061598 Immunodeficiency Diseases 0.000 claims description 7
208000029462 Immunodeficiency disease Diseases 0.000 claims description 7
230000001580 bacterial effect Effects 0.000 claims description 7
239000012592 cell culture supplement Substances 0.000 claims description 7
230000007813 immunodeficiency Effects 0.000 claims description 7
229930182566 Gentamicin Natural products 0.000 claims description 6
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 6
239000013589 supplement Substances 0.000 claims description 6
241000283707 Capra Species 0.000 claims description 5
206010035664 Pneumonia Diseases 0.000 claims description 5
241000713325 Visna/maedi virus Species 0.000 claims description 5
229960002518 gentamicin Drugs 0.000 claims description 5
230000000750 progressive effect Effects 0.000 claims description 5
241000713730 Equine infectious anemia virus Species 0.000 claims description 4
210000001744 T-lymphocyte Anatomy 0.000 claims description 4
239000012888 bovine serum Substances 0.000 claims description 4
206010014599 encephalitis Diseases 0.000 claims description 4
230000002401 inhibitory effect Effects 0.000 claims description 4
108010002350 Interleukin-2 Proteins 0.000 claims description 3
206010003246 arthritis Diseases 0.000 claims description 3
239000012679 serum free medium Substances 0.000 claims description 3
239000002775 capsule Substances 0.000 claims 1
238000012258 culturing Methods 0.000 claims 1
230000007812 deficiency Effects 0.000 claims 1
238000010899 nucleation Methods 0.000 claims 1
241000894006 Bacteria Species 0.000 abstract description 4
230000010261 cell growth Effects 0.000 abstract description 4
230000002708 enhancing effect Effects 0.000 abstract description 2
239000002609 medium Substances 0.000 description 9
241000283690 Bos taurus Species 0.000 description 5
229940088710 antibiotic agent Drugs 0.000 description 5
241000282324 Felis Species 0.000 description 4
241000282326 Felis catus Species 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
241001465754 Metazoa Species 0.000 description 3
238000002965 ELISA Methods 0.000 description 2
241000283086 Equidae Species 0.000 description 2
241001494479 Pecora Species 0.000 description 2
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
208000009724 equine infectious anemia Diseases 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000003292 kidney cell Anatomy 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000007170 pathology Effects 0.000 description 2
241000894007 species Species 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
208000030507 AIDS Diseases 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
241000713704 Bovine immunodeficiency virus Species 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
241001272567 Hominoidea Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000282553 Macaca Species 0.000 description 1
241000194105 Paenibacillus polymyxa Species 0.000 description 1
108010040201 Polymyxins Proteins 0.000 description 1
241000272171 Scolopacidae Species 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229940053050 neomycin sulfate Drugs 0.000 description 1
244000052769 pathogen Species 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000000565 sealant Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000008467 tissue growth Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Wood Science & Technology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Immunology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

BG108315A 2001-05-10 2003-11-05 Състав и метод за повишаване на клетъчната гъстота в клетъчни култури, инфектирани с lentivirus BG108315A (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US29009601P	2001-05-10	2001-05-10

Publications (1)

Publication Number	Publication Date
BG108315A true BG108315A (bg)	2005-03-31

Family

ID=23114512

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108315A BG108315A (bg)	2001-05-10	2003-11-05	Състав и метод за повишаване на клетъчната гъстота в клетъчни култури, инфектирани с lentivirus

Country Status (25)

Country	Link
US (1)	US7160721B2 (cs)
EP (2)	EP2298343A1 (cs)
JP (1)	JP4283544B2 (cs)
KR (1)	KR20040029981A (cs)
CN (1)	CN1326992C (cs)
AT (1)	ATE521364T1 (cs)
AU (1)	AU2002342568B2 (cs)
BG (1)	BG108315A (cs)
BR (1)	BR0209482A (cs)
CA (1)	CA2446131C (cs)
CY (1)	CY1112123T1 (cs)
CZ (1)	CZ20033046A3 (cs)
DK (1)	DK1385540T3 (cs)
ES (1)	ES2369846T3 (cs)
HR (1)	HRP20030974A2 (cs)
HU (1)	HUP0400283A2 (cs)
MX (1)	MXPA03010208A (cs)
NO (1)	NO20034961L (cs)
NZ (1)	NZ529326A (cs)
PL (1)	PL373847A1 (cs)
PT (1)	PT1385540E (cs)
SI (1)	SI1385540T1 (cs)
WO (1)	WO2002091994A2 (cs)
YU (1)	YU88703A (cs)
ZA (1)	ZA200309556B (cs)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10920483B2 (en)	2018-10-25	2021-02-16	Mark Mutchnik	Window seal for preventing water penetration
EP4277933A4 (en)	2021-01-14	2024-12-11	Senti Biosciences, Inc.	SECRETABLE PAYLOAD REGULATION

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4215107A (en) *	1978-12-29	1980-07-29	Merck & Co., Inc.	Parainfluenza virus vaccine and its preparation
JPS57194787A (en) *	1981-05-28	1982-11-30	Ajinomoto Co Inc	Culture medium for animal cell
US6107077A (en)	1987-08-26	2000-08-22	Yamamoto; Janet K.	Feline lymphoid cell lines capable of producing FIV for FIV diagnostics and vaccines
AU640511B2 (en) *	1990-07-30	1993-08-26	Pharmacia & Upjohn Company	Hexa-n-(o-hydroxybenzyl) neomycin b for inhibiting human retroviruses and for the treatment of aids
JPH08502966A (ja) *	1992-10-23	1996-04-02	ユニバーシティー・オブ・マサチューセッツ・メディカル・センター	Ｒｎａ／リガンド結合の低分子抑制
US5534408A (en) *	1993-09-24	1996-07-09	University Of Massachusetts Medical Center	2-deoxystreptamine aminoglycoside inhibition of HIV RRE/Rev binding
PT759780E (pt)	1994-05-10	2001-01-31	American Home Prod	Vacina melhorada de vsrb vivo modificado
DE69636440D1 (de)	1995-08-25	2006-09-21	Univ Florida	IL-2 unabhängige T-Zellen der Katze

2002
- 2002-05-03 BR BRPI0209482-7A patent/BR0209482A/pt not_active IP Right Cessation
- 2002-05-03 AT AT02769679T patent/ATE521364T1/de active
- 2002-05-03 JP JP2002588913A patent/JP4283544B2/ja not_active Expired - Lifetime
- 2002-05-03 PT PT02769679T patent/PT1385540E/pt unknown
- 2002-05-03 HR HR20030974A patent/HRP20030974A2/hr not_active Application Discontinuation
- 2002-05-03 DK DK02769679.8T patent/DK1385540T3/da active
- 2002-05-03 EP EP10183838A patent/EP2298343A1/en not_active Withdrawn
- 2002-05-03 PL PL02373847A patent/PL373847A1/xx not_active Application Discontinuation
- 2002-05-03 HU HU0400283A patent/HUP0400283A2/hu unknown
- 2002-05-03 CA CA2446131A patent/CA2446131C/en not_active Expired - Lifetime
- 2002-05-03 EP EP02769679A patent/EP1385540B1/en not_active Expired - Lifetime
- 2002-05-03 ES ES02769679T patent/ES2369846T3/es not_active Expired - Lifetime
- 2002-05-03 CZ CZ20033046A patent/CZ20033046A3/cs unknown
- 2002-05-03 SI SI200230960T patent/SI1385540T1/sl unknown
- 2002-05-03 AU AU2002342568A patent/AU2002342568B2/en not_active Expired
- 2002-05-03 CN CNB028096002A patent/CN1326992C/zh not_active Expired - Lifetime
- 2002-05-03 MX MXPA03010208A patent/MXPA03010208A/es active IP Right Grant
- 2002-05-03 NZ NZ529326A patent/NZ529326A/en not_active IP Right Cessation
- 2002-05-03 KR KR10-2003-7014613A patent/KR20040029981A/ko not_active Ceased
- 2002-05-03 WO PCT/US2002/014271 patent/WO2002091994A2/en not_active Ceased
- 2002-05-03 YU YU88703A patent/YU88703A/sh unknown
- 2002-05-07 US US10/140,172 patent/US7160721B2/en not_active Expired - Lifetime
2003
- 2003-11-05 BG BG108315A patent/BG108315A/bg unknown
- 2003-11-07 NO NO20034961A patent/NO20034961L/no not_active Application Discontinuation
- 2003-12-09 ZA ZA200309556A patent/ZA200309556B/xx unknown
2011
- 2011-09-23 CY CY20111100925T patent/CY1112123T1/el unknown

Also Published As

Publication number	Publication date
JP4283544B2 (ja)	2009-06-24
CA2446131A1 (en)	2002-11-21
US20020197714A1 (en)	2002-12-26
CZ20033046A3 (en)	2004-03-17
DK1385540T3 (da)	2011-10-24
EP1385540B1 (en)	2011-08-24
CN1514734A (zh)	2004-07-21
PT1385540E (pt)	2011-10-21
WO2002091994A2 (en)	2002-11-21
SI1385540T1 (sl)	2011-10-28
CA2446131C (en)	2013-07-02
HRP20030974A2 (en)	2004-02-29
ZA200309556B (en)	2005-02-23
ES2369846T3 (es)	2011-12-07
MXPA03010208A (es)	2004-03-10
NZ529326A (en)	2006-09-29
NO20034961L (no)	2003-12-01
NO20034961D0 (no)	2003-11-07
CY1112123T1 (el)	2015-11-04
US7160721B2 (en)	2007-01-09
CN1326992C (zh)	2007-07-18
AU2002342568B2 (en)	2007-11-01
JP2005508139A (ja)	2005-03-31
HUP0400283A2 (en)	2007-08-28
EP1385540A4 (en)	2004-12-01
EP1385540A2 (en)	2004-02-04
PL373847A1 (en)	2005-09-19
KR20040029981A (ko)	2004-04-08
YU88703A (sh)	2006-05-25
WO2002091994A3 (en)	2003-05-08
EP2298343A1 (en)	2011-03-23
BR0209482A (pt)	2007-01-02
ATE521364T1 (de)	2011-09-15

Publication	Publication Date	Title
Schuetze et al.	1993	The Ets-related transcription factor PU. 1 immortalizes erythroblasts
Konigsberg	1979	[45] Skeletal myoblasts in culture
EA200200604A1 (ru)	2002-12-26	Производство вакцин
Richard et al.	2001	Humoral hypercalcemia of malignancy: severe combined immunodeficient/beige mouse model of adult T-cell lymphoma independent of human T-cell lymphotropic virus type-1 tax expression
BG108315A (bg)	2005-03-31	Състав и метод за повишаване на клетъчната гъстота в клетъчни култури, инфектирани с lentivirus
Ball et al.	1957	Development in vitro of isolated oocysts of Plasmodium relictum
AU2002342568A1 (en)	2003-05-01	Composition and method for increasing cell density in cell cultures infected with lentivirus
CN114891718B (zh)	2024-01-30	用于悬浮培养骨髓细胞的培养基、制备方法、应用和诱导骨髓源细胞分化为巨噬细胞的方法
CN106497863B (zh)	2019-10-11	一种大鼠角膜内皮细胞的分离、纯化及培养方法
Albright et al.	1980	In vitro growth of Trypanosoma musculi in cellfree medium conditioned by rodent macrophages and mercaptoethanol
CN115747138B (zh)	2024-03-08	一种hek 293细胞培养基及其应用
CN1700929A (zh)	2005-11-23	含有禽吸收障碍综合征相关病毒的疫苗及其给药方法
EP4594466A1 (en)	2025-08-06	A method of culturing lawsonia intracellularis bacteria
Yu et al.	2005	Long-term effects on HEK-293 cell line after co-culture with porcine endogenous retrovirus
CN107142238B (zh)	2018-04-24	组蛋白去乙酰化酶抑制剂在细胞培养中的用途及细胞培养基
US20250027038A1 (en)	2025-01-23	Culture method of fish germ stem cells
Chan et al.	1974	Mammalian sarcoma-leukemia viruses. I. Infection of feline, bovine, and human cell cultures with Snyder-Theilen feline sarcoma virus
US5112756A (en)	1992-05-12	Continuous production of bovine Maedi-Visna-like viral antigens in Cf2Th cells
AU2005308583A1 (en)	2006-06-01	Methods for cultivating Lawsonia intracellularis
Spooncer et al.	1997	Culturing primitive hemopoietic cells: Long-term mouse marrow cultures and the establishment of factor-dependent (FDCP-Mix) hemopoietic cell lines
US5338680A (en)	1994-08-16	Non-producer cell lines transformed by AMV
SU1542955A1 (ru)	1990-02-15	Способ культивирования лимфоидных клеток человека линии вал
SU1360193A1 (ru)	1989-08-07	Штамм культивируемых клеток почки эмбриона человека дл накоплени и титровани вируса клещевого энцефалита
Simeonov et al.	2021	Effects of chicken anaemia virus on experimental leukosis, induced by avian myelocytomatosis virus MC29.
CN116694571A (zh)	2023-09-05	一种无异种t细胞培养基及其制备方法和应用